Capital Research Global Investors Portfolio holdings
Capital Research Global Investors (CRGI), a division of Capital Group established in 1931 and headquartered in Los Angeles, California, is a powerhouse in active investment management, overseeing hundreds of billions in assets with a focus on global equity portfolios. Known for its long-term, research-intensive approach, CRGI employs a unique multiple-portfolio-manager system to diversify risk and enhance returns, serving institutional clients, financial advisors, and individual investors through vehicles like the American Funds mutual fund family. The firm’s investment philosophy emphasizes fundamental analysis and a deep understanding of companies worldwide, aiming to identify growth opportunities over extended horizons. As part of Capital Group’s broader mission, CRGI has built a reputation for delivering consistent, value-driven results in the global investment landscape.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$5.5B |
| 2 |
UBS Group
UBS
|
+$1.65B |
| 3 |
JPMorgan Chase
JPM
|
+$1.33B |
| 4 |
Goldman Sachs
GS
|
+$976M |
| 5 |
Teva Pharmaceuticals
TEVA
|
+$939M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amgen
AMGN
|
+$2.02B |
| 2 |
Digital Realty Trust
DLR
|
+$1.33B |
| 3 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$981M |
| 4 |
AET
Aetna Inc
AET
|
+$831M |
| 5 |
Texas Instruments
TXN
|
+$815M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 16.85% |
| 2 | Technology | 13.64% |
| 3 | Financials | 11.28% |
| 4 | Communication Services | 10.33% |
| 5 | Energy | 10.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
51
UBS Group
UBS
$177B
| $1.71B | 0.55% |
+109,253,117
| New | +$1.65B |
|
52
Chevron
CVX
$386B
| $1.67B | 0.54% |
14,203,265
-906,539
| -6% | -$98.7M |
|
53
IBM
IBM
$222B
| $1.63B | 0.53% |
10,263,233
-726,227
| -7% | -$111M |
|
54
BioMarin Pharmaceuticals
BMRN
$13.6B
| $1.63B | 0.53% |
19,643,043
-573,172
| -3% | -$49.3M |
|
55
Berkshire Hathaway Class B
BRK.B
$1.09T
| $1.61B | 0.52% |
9,903,133
+1,103,013
| +13% | +$170M |
|
|
56
Teva Pharmaceuticals
TEVA
$42.8B
| $1.61B | 0.52% |
44,396,747
+23,520,998
| +113% | +$939M |
|
57
Las Vegas Sands
LVS
$29.6B
| $1.59B | 0.52% |
29,838,253
+1,054,397
| +4% | +$61.4M |
|
58
Caterpillar
CAT
$393B
| $1.51B | 0.49% |
16,298,180
-1,103,080
| -6% | -$100M |
|
|
VIAB
59
DELISTED
Viacom Inc. Class B
VIAB
| $1.49B | 0.48% |
42,513,714
+1,735
| +0% | +$63.7K |
|
60
Costco
COST
$421B
| $1.48B | 0.48% |
9,240,171
-109,500
| -1% | -$16.7M |
|
61
Western Union
WU
$2.23B
| $1.42B | 0.46% |
65,346,913
-732,615
| -1% | -$15.2M |
|
62
Microsoft
MSFT
$3.66T
| $1.4B | 0.45% |
22,499,205
+1,514
| +0% | +$91.1K |
|
63
Wells Fargo
WFC
$269B
| $1.39B | 0.45% |
25,239,466
+18,266,087
| +262% | +$918M |
|
|
PXD
64
DELISTED
Pioneer Natural Resource Co.
PXD
| $1.37B | 0.44% |
7,582,003
+215,001
| +3% | +$39.4M |
|
65
McDonald's
MCD
$195B
| $1.35B | 0.44% |
11,100,003
+135,899
| +1% | +$15.9M |
|
66
Exelon
EXC
$46.6B
| $1.27B | 0.41% |
50,136,548
-27,190,675
| -35% | -$645M |
|
|
VALE.P
67
DELISTED
Vale S A
VALE.P
| $1.27B | 0.41% |
183,602,433
+27,198,000
| +17% | +$180M |
|
68
Prudential Financial
PRU
$42.3B
| $1.25B | 0.41% |
12,045,305
+6,834,373
| +131% | +$648M |
|
|
NLSN
69
DELISTED
Nielsen Holdings plc
NLSN
| $1.16B | 0.38% |
27,723,831
+749,241
| +3% | +$34.4M |
|
70
Mastercard
MA
$490B
| $1.12B | 0.36% |
10,865,251
+3,851,593
| +55% | +$399M |
|
71
Nike
NKE
$60.1B
| $1.11B | 0.36% |
21,857,127
+5,568,520
| +34% | +$286M |
|
72
Duke Energy
DUK
$96.3B
| $1.05B | 0.34% |
13,572,410
-3,273,208
| -19% | -$251M |
|
73
Citigroup
C
$231B
| $1.03B | 0.33% |
17,375,987
+3,405,283
| +24% | +$184M |
|
74
APA Corp
APA
$14B
| $1.03B | 0.33% |
16,259,528
+856,968
| +6% | +$54M |
|
75
ConocoPhillips
COP
$153B
| $1.03B | 0.33% |
20,466,746
-3,292,812
| -14% | -$152M |
|
Similar funds
Capital Research Global Investors's Q4 2016 Portfolio in Review
As of Q4 2016, Capital Research Global Investors held 465 positions worth $308B, up 2% from $303B the previous quarter. Its ten largest holdings account for 23% of the portfolio.
Capital Research Global Investors's Q4 2016 filing shows 52 new, 126 increased, 139 reduced and 38 closed positions. Its largest new stake was Broadcom: 317,484,320 shares worth $5.61B. The largest sale was Amgen, an estimated $2.02B.
By sector, the portfolio is most concentrated in Healthcare at 17% of assets, down from 19% a quarter earlier, followed by Technology and Financials.
- Capital Research Global Investors's largest Q4 2016 buy was Broadcom: 317,484,320 shares worth $5.61B.
- Capital Research Global Investors added most to JPMorgan Chase in Q4 2016, an estimated $1.33B increase.
- Capital Research Global Investors's biggest Q4 2016 reduction was Amgen, cutting an estimated $2.02B.
- Capital Research Global Investors fully exited Digital Realty Trust in Q4 2016, selling an estimated $1.33B.
- Capital Research Global Investors's ten largest holdings make up 23% of its $308B portfolio in Q4 2016.
- Capital Research Global Investors opened 52 new positions and closed 38 in Q4 2016.
- Capital Research Global Investors's portfolio value rose 2% quarter-over-quarter to $308B.
Based on Capital Research Global Investors's 13F filing for Q4 2016, filed 15 Feb 2017.